As-Needed ICS Therapy in Mild Asthma
This interactive module covers the unique issues, controversies, gaps and challenges around the clinical application of as-needed inhaled corticosteroids (ICS) in mild and moderate-severe asthma. Evidence regarding symptom-driven, as-needed use of ICS in asthma has been mounting in recent years, and as a result substantive changes have occurred in guideline-based recommendations. The application of this alternative method may differ based on location (U.S. vs International) and population (Pediatric vs Adult). The module starts with case and evidence presentations, followed by the treatment options, and also explores current challenges from different perspectives. The module enhances clinician understanding of the practical application of as-needed ICS therapy and its current state.
This course is an edited and enhanced recording of the ATS 2021 International Conference session with the same name.
Clinicians (physicians, nurses, fellows, residents), researchers, administrators, and policymakers: anyone involved in the delivery of care and the science of patients with asthma
After successfully completing this module, learners will be able to:
- Discuss the evidence supporting as-needed ICS therapy for symptom-driven asthma.
- Adapt and apply clinical strategies for symptom-driven, as-needed ICS therapy in asthma for different perspectives (pediatrics vs adults) and in different populations.
- Identify implementation gaps in care in their respective practices and begin to address those gaps.
- Identify remaining research opportunities/needs in mild asthma.
|Anne E. Dixon, MA, BM BCh, ATSF||Professor of Medicine||University of Vermont Larner College of Medicine||Chair; Presenter||MitoQ: Research - investigator initiated|
NIH: Advisory Committee - non-promotional
ABIM: Advisory Committee - non-promotional
|Kaharu Sumino, MD, MPH||Associate Professor of Medicine||Washington University School of Medicine, St. Louis, MO||Chair; Presenter||None|
|Helen K. Reddel. MD||Professor; Chair, GINA Science Committee||Woolcock Institute of Medical Research, Sydney, Australia||Chair; Presenter||GlaxoSmithKline: Speaker/faculty - non-promotional purpose|
Teva: Speaker/faculty - non-promotional purpose
Novartis: Advisory Committee - non-promotional, Research - investigator initiated
AstraZeneca: Advisory Committee - non-promotional, Speaker/faculty - non-promotional purpose, Research - investigator initiated
GlaxoSmithKline: Research - investigator initiated
Chiesi: Advisory Committee - non-promotional
Sanofi: Advisory Committee - non-promotional
|Stanley J. Szefler, MD||Director, Pediatric Asthma Research Program||University of Colorado School of Medicine||Chair; Presenter||Astra Zeneca: Advisory Committee - non-promotional|
Sanofi: Advisory Committee - non-promotional
Moderna: Advisory Committee - non-promotional
Regeneron: Advisory Committee - non-promotional
GlaxoSmithKline: Advisory Committee - non-promotional
Propeller Health: Research - investigator initiated
The American Thoracic Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
It is the policy of the ATS to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. As an accredited CME provider, the ATS requires that its planners, reviewers and presenters comply with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. The ATS also requires specific disclosure of relationships with companies and organizations associated with tobacco or cannabis and prohibits or limits participation of faculty in official ATS activities, including CME, if any tobacco industry relationship or some types of cannabis industry relationships are present. To see the most recent policies regarding potential conflicts of interest as well as the mechanisms to resolve such conflicts, press the COI Policy link below.
This educational activity may include discussion of unapproved uses of a drug, product, or device. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Instructions to Receive Credit
To earn credit for this course, follow these instructions:
- Launch and complete all modules by viewing every page in the module.
- After you complete the module(s), the post test will become available. You must pass the post these with a 70% score or better.
- Complete the Course Evaluation.
- Once you complete the modules, pass the post test and complete the evaluation, the system will grant you credit.
- To view your transcript and print your certificate, go to the My Account drop-down list. Then select Transcript.
- 1.50 AMA PRA Category 1 Credit(s)™The American Thoracic Society designates this for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.50 Participation